fashion -WSS

fashion

author：focus 2025-10-01 15:29:37 - browse：4978

Five elderly people have been blinded in one eye by a severe side effect after receiving injections of a newly approved treatment for eye disease from Apellis Pharmaceuticals. The frequency of this side effect — a severe type of eye inflammation — is low but its cause remains unknown.

The new safety information related to the Apellis drug, called Syfovre, was presented Saturday by a committee of eye disease experts at the annual meeting of the American Society of Retinal Specialists (ASRS).

Apellis cooperated with the ASRS analysis but the company also announced its own internal review Saturday that found fewer cases of retinal occlusive vasculitis, a type of severe eye inflammation that blocks blood flow to the retina and can result in blindness. The rate of retinal occlusive vasculitis reported remains “very rare,” the company said, adding that there is no evidence linking the drug product or its manufacturing to the severe side effect.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Today's health inequities arise from racist U.S. history, say experts

knowledge

entertainment

WSS

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Senate HELP committee spars over health care workforce policies

What health policies could hitch a ride on a spending bill?

Experts study whether long Covid risk adds up with each reinfection

Readout LOUD podcast: possible new ALS drug, artificial wombs

Readout LOUD podcast: possible new ALS drug, artificial wombs

leisure time

fashion

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

CDC advisers recommend seasonal use of Pfizer RSV shot

23andMe had bad news about my health. I wish a person had delivered it

Medical school prerequisites are outdated

The high cost of giving birth even with insurance

EpiPen alternative approval delay highlights citizen petition issue

Sports medicine is finally prioritizing gender equality

Medicare’s new pay boost for primary care is angering specialists

Trump demands the U.S. pay no more for drugs than other countries … again

Study suggests Covid rebound is far more common with Paxlovid than without

entertainment

FDA reorg will put new emphasis on investigations, sources say

Readout Newsletter: Zepbound, Valneva's vaccine, and more

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

EpiPen alternative approval delay highlights citizen petition issue

Biotech lab space demand falls sharply

Today's health inequities arise from racist U.S. history, say experts

knowledge

entertainment

explore

focus